PRESS RELEASE
Biotest AG increases sales by 32% in the 2023 financial year
Dreieich, March 28, 2024. In the 2023 financial year, the Biotest Group generated sales of €684. 6 million, compared to €516. 1 million last year. This corresponds to a significant profit increase of 32. 7%. This expansion in profit is mainly due to the profit generated by disclosure and generation progression of Grifols, S. A. , which amounted to €190. 1 million according to the transfer of generation and license agreement. Excluding the profits generated by disclosure and generation progression of Grifols, S. A. , a turnover of €494. 5. Million. This corresponds to a reduction of 4. 2% compared to last year.
The new intravenous immunoglobulin Yimmugo® had a positive effect with sales of €27. 2 million. Yimmugo® was effectively introduced in November 2022 and is now the first end-use product to be produced using a state-of-the-art production procedure in the new Biotest. Next Level production facility at the Dreieich plant in Germany.
For the Biotest Group, an overall profit before tax (EBT) of €106. 3 million was recorded, compared to €-30. 8 million last year.
The year after 2023 paves the way for the intensification of collaboration with the majority shareholder Grifols, S. A. The aim is to deepen integration in the spaces of study and progression, production and marketing and distribution, while maintaining the respective interests of the two companies. The most important contracts were for outreach and generational progress. with Grifols, S. A.
Since November 2022, Yimmugo® intravenous immunoglobulin has been the first end-use product to be produced using a state-of-the-art production procedure at Biotest Next Level’s new production facility at the Dreieich facility in Germany. In September 2023, Biotest reached a vital milestone in the marketing authorization procedure for Yimmugo® in the U. S. UU. La U. S. Food and Drug AdministrationThe U. S. Food and Drug Administration (FDA) has notified Biotest that it is accepting the Biologics License Application (BLA) for Yimmugo® for review. The MA application covers immunodeficiency indication number one. (PID).
In December 2023, the FDA conducted Pre-Authorization Inspection (PLI) of the Biotest Next Level facility. Among other areas, the quality systems, Yimmugo’s® new production facility in the construction of Biotest Next Level and the overall compliance of the production processes with the submitted dossier was inspected and reviewed. A document summarizing the effects of this inspection is ready as part of the authorization process. Further steps towards a biological license application (BLA) will be finalized in 2024.
Biotest develops fibrinogen for use in cases of congenital and acquired fibrinogen deficiency. In mid-February 2024, Biotest announced that the fibrinogen “AdFIrst study” had reached its number one endpoint.
Perspectives:
For the 2024 financial year, the Board of Directors expects profit to expand by more than single digits compared to 2023, adding the disclosure profit and generation progression of Grifols, S. A.
As a result, the Executive Board expects an operating profit (EBIT) of between €80 million and €100 million by 2024.
About Biotest
Biotest is a supplier of biologic drugs derived from human plasma. With an added price chain that extends from clinical and preclinical progression to global sales, Biotest specializes primarily in the fields of clinical immunology, hematology, and critical care medicine. Biotest develops and markets immunoglobulins, clotting sites and albumin based on human blood plasma. They are used to treat diseases of the immune system and hematopoietic. Biotest has more than 2,400 employees worldwide. The shares and listed shares of Biotest AG are indexed in the Prime Standard of the German Stock Exchange. Since May 2022, Biotest has been part of the Grifols Group, Barcelona, Spain (www. grifols. com).
Public Relations Contact
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www. biotest. com